Healthcare Industry News: SBRT
News Release - June 13, 2013
First U.S. Center to Treat a Patient with the new CyberKnife(R) M6(TM) SystemLancaster General Health Unveils Leading Robotic Radiosurgery System
SUNNYVALE, Calif., June 13, 2013 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today that Lancaster General Health in Pennsylvania is the first U.S. center to treat a patient with the CyberKnife® M6™ System, the most advanced robotic radiosurgery system in the world and the latest generation of the CyberKnife System. The new CyberKnife M6 System was designed to provide clinicians with an enhanced stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) solution that targets tumors non-invasively with precisely delivered, high doses of radiation that spare healthy tissue and minimize disruption to patients' lives.
The CyberKnife M6 System is a non-surgical option for many patients who have inoperable or surgically complex tumors, or who seek an alternative to surgery. In addition to the unmatched clinical capabilities of the previous CyberKnife System, afforded by non-isocentric, non-coplanar robotic beam delivery and real-time tracking and automatic correction for tumor motion, the redesigned M6 System can direct beams from a wider angle around the patient and provides a streamlined user interface for treatment delivery. The result is a system that enables the precise radiosurgical treatment of tumors anywhere in the body with minimal radiation exposure to surrounding healthy tissue and organs.
"Two weeks ago we successfully treated a patient with a liver tumor with our new CyberKnife M6 System. We have seen firsthand the positive outcomes we can achieve for our patients," said Jeffrey S. Eshleman, MD, Director of Radiation Oncology, Lancaster General Health . "We look forward to bringing this technology to more patients and providing them with enhanced quality and highly precise radiation therapy treatments."
"Accuray developed the CyberKnife M6 System to meet the radiation oncologist's growing need for an efficient, accurate and flexible treatment option that can be applied to a wide variety of patients," said Joshua H. Levine, president and chief executive officer of Accuray. "On the heels of adoption in Europe, we are pleased to be working with Lancaster General Health to lead the way for patients in the U.S. to receive personalized radiation treatment."
The Ann B. Barshinger Cancer Institute, part of Lancaster General Health, is a state of the art, two-story, 70,000 square foot facility opening in July 2013 in Lancaster, Pa. The new center will provide advanced technology and integration of cancer care, bringing medical oncologists, radiation oncologists, surgeons and other cancer specialists together in one, centralized location with access to existing services, including the Suzanne H. Arnold Center for Breast Health. The new Cancer Institute will feature a new radiation wing with the latest diagnostic and treatment technologies, including the new CyberKnife M6 System.
Accuray Incorporated (ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to advantages of new technology, clinical applications, clinical results, patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on November 8, 2012, February 6, 2013, and May 9, 2013 and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Educates Radiation Oncology Practices on the Potential Impact of the Proposed Alternative Payment Model (RO-APM)
Swiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems
Accuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System